Cocrystal Pharma Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 10, 2019 08:35 ET
|
Cocrystal Pharma, Inc.
– Company is well positioned to achieve multiple corporate, clinical and research value-driving milestones in 2019 – BOTHELL, WA, May 10,...
Cocrystal Pharma Reports 2018 Financial Results and Provides Corporate Overview and Business Outlook
April 01, 2019 08:35 ET
|
Cocrystal Pharma, Inc.
– Exclusive worldwide license and collaboration agreement with Merck further validates Company’s approach to creating first- and best-in-class antiviral drugs and expected to enable rapid advancement...
Cocrystal Pharma Announces Closing of Private Placement
March 11, 2019 08:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, March 11, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Provides Update on Clinical Development Program Evaluating CC-31244 for Ultra-Short Treatment of Hepatitis C Virus
January 22, 2019 08:00 ET
|
Cocrystal Pharma, Inc.
- Hepatitis C program designed to develop ultra-short treatment for hepatitis C virus (HCV) consisting of CC-31244, an oral, potent, broad-spectrum non-nucleoside inhibitor, as a part of combination...
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
January 03, 2019 08:30 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Presentation at the RespiDART 2018: Frontiers in Drug Development Against Respiratory Viruses Conference
November 30, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
- Proprietary technology has the ability to fuel Cocrystal’s pipeline by effectively creating small molecule antiviral therapeutics that are safe, effective, convenient to administer and have the...
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
November 15, 2018 13:37 ET
|
Schall Law
LOS ANGELES, Nov. 15, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cocrystal Pharma, Inc....
Cocrystal Pharma Announces Presentation of Preclinical Characterization Data of CC-42344 at the 6th ISIRV-AVG Conference
November 13, 2018 11:50 ET
|
Cocrystal Pharma, Inc.
- Company’s novel, broad spectrum influenza antivirals specifically designed to be effective against all significant A strains of the influenza virus - - CC-43244, Company’s lead molecule has...
Cocrystal Pharma Reports 2018 Third Quarter Financial Results and Provides Corporate Update
November 12, 2018 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, WA, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or the “Company”), a clinical stage biotechnology company discovering and developing novel...
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Cocrystal Pharma, Inc. (Formerly BioZone Pharmaceuticals, Inc.) and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
November 10, 2018 08:28 ET
|
Schall Law
LOS ANGELES, Nov. 10, 2018 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Cocrystal Pharma, Inc....